Company
Genetic Technologies Limited
ASX:GTG
Genetic Technologies Ltd (ASX:GTG; NASDAQ:GENE) is a diversified molecular diagnostics company. The company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world.
67 stories
Imugene taps experienced life sciences CFO for newly created in-house role
Tonroe has extensive experience as a CFO and company secretary in the biopharmaceutical industry and brings international finance leadership experience from his time in the US, Canada, the UK and Hong Kong.
Genetic Technologies genetic test could determine those at high risk of contracting COVID-19
A vaccine for COVID-19 is expected to take a long time to develop and the company is confident its genetic test will be another bullet in the armoury to fight the virus in the meantime.
Genetic Technologies surges after colorectal and breast cancer genetic risk tests
The breast cancer and colorectal tests will provide healthcare providers and their patients with risk assessments of the patient developing breast cancer.
Genetic Technologies tops ASX Most Traded ahead of Nasdaq trading
Genetic Technologies has traded $1.7 million of stock by noon.
Genetic Technologies transitioning to an e-commerce platform
The company provides a risk assessment test for non-hereditary breast cancer.
Genetic Technologies’ shares surge on launching promotional campaign
The company’s lead product is a risk assessment test for non-hereditary breast cancer.
Genetic Technologies to promote breast cancer test with Pippa Mann
The IndyCar racing driver is serving for a second consecutive term.
Genetic Technologies raising $8.1M for cancer risk assessment tests
Genetic Technologies (ASX:GTG) has received commitments to raise $8.1 million from professional and sophisticated investors in the U.S. at $0.0113 per share.